FIELD: biotechnology.
SUBSTANCE: invention relates to adaptive cellular immunotherapy, and can be used in medicine for cancer immunotherapy. In order to obtain engineered primary T-cells for the treatment of cancer using immunotherapy, a nucleic acid containing an exogenous polynucleotide sequence encoding an HLA-G or HLA-E molecule is introduced into these primary T-cells, which should be integrated into the endogenous beta2m locus and specific with respect to a reagent sequence that specifically targets the said selected endogenous locus, and provides the said T-cells with a chimeric antigen receptor (CAR) targeted to an antigen expressed on the surface of tumor cells of the said cancer.
EFFECT: invention makes it possible to obtain safer primary T-cells with increased therapeutic potential.
18 cl, 21 dwg, 13 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| HLA-NON-RESTRICTED T-CELL RECEPTORS AND THEIR USE | 2019 |
|
RU2812917C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| NON-DESTRUCTIVE GENE THERAPY FOR TREATING MMA | 2018 |
|
RU2820602C2 |
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
